Literature DB >> 18775590

Bazex syndrome (acrokeratosis paraneoplastica): persistence of cutaneous lesions after successful treatment of an associated oropharyngeal neoplasm.

Adekunmi Fasanmade1, Keith Farrell, Charles S Perkins.   

Abstract

Acrokeratosis paraneoplastica is a rare paraneoplastic syndrome commonly affecting males over 40 years of age. There exists a strong association with squamous cell carcinoma (SCC) of the upper aerodigestive tract or cervical metastatic disease originating from an unknown primary. We report a case associated with SCC of the right tonsil with persistent paraneoplastic cutaneous lesions 2 years after successful treatment of the underlying neoplasm.

Entities:  

Mesh:

Year:  2008        PMID: 18775590     DOI: 10.1016/j.bjoms.2008.07.190

Source DB:  PubMed          Journal:  Br J Oral Maxillofac Surg        ISSN: 0266-4356            Impact factor:   1.651


  5 in total

1.  Piriform sinus carcinoma with a paraneoplastic syndrome misdiagnosed as adult onset Still's disease: a case report.

Authors:  Liu Yang; Wen Li; Jintao Du
Journal:  Int J Clin Exp Med       Date:  2015-10-15

2.  Acrokeratosis paraneoplastica in serous ovarian carcinoma: case report.

Authors:  Aline Hempen; Eleftherios P Samartzis; Jivko Kamarachev; Daniel Fink; Konstantin J Dedes
Journal:  BMC Cancer       Date:  2015-07-08       Impact factor: 4.430

3.  [In search of the lost tumour].

Authors:  Rebeca de la Fuente Cañibano; Jorge Crespo Del Hierro
Journal:  Aten Primaria       Date:  2019-05-23       Impact factor: 1.137

4.  Clinical characteristics of paraneoplastic syndromes in patients with head and neck cancer.

Authors:  Wenwen Diao; Ya Liang; Liming Gao; Yingying Zhu; Xiaoli Zhu; Shuting Yu; Xin Xia; Xingming Chen
Journal:  Laryngoscope Investig Otolaryngol       Date:  2022-07-06

5.  Bazex syndrome.

Authors:  Ismael Alves Rodrigues; Letícia Trivellato Gresta; Rafaela Carolina Cruz; Giselly Gomes Carvalho; Melissa Heringer Chamon Barros Quintão Moreira
Journal:  An Bras Dermatol       Date:  2013 Nov-Dec       Impact factor: 1.896

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.